CD82, and CD63 in thyroid cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• CD82 (KAI1) and CD63 (ME491) are transmembrane 4 superfamily proteins implicated in cancer progression.
• CD82 is a potential prostate cancer metastasis suppressor, and CD63 is involved in melanoma progression.
• Down-regulation of CD82 and CD63 is associated with metastatic potential in various solid tumors, but their role in thyroid carcinogenesis is unclear.

Purpose of the Study:

• To investigate the expression of CD82 and CD63 in thyroid carcinoma.
• To determine if CD82 and CD63 expression can serve as prognostic indicators for thyroid cancer metastasis.

Main Methods:

• Reverse transcriptase-PCR (RT-PCR) and immunohistochemistry were used to analyze CD82 and CD63 expression.
• Tissues from benign goiter (n=12) and 75 primary thyroid carcinoma specimens (PTC, FTC, UTC) were analyzed.
• Specimens included non-metastasized (n=36) and metastasized (n=39) tumors.

Main Results:

• CD82 expression was present in all benign goiter tissues but significantly decreased in thyroid carcinoma tissues (p<0.001).
• Down-regulation of CD82 was also observed in metastasized tumors compared to non-metastasized tumors (p<0.05).
• CD82 expression correlated with pTNM status and pathological stage. CD63 expression was unchanged and showed no correlation with clinical or pathological parameters.

Conclusions:

• Down-regulation of CD82 expression correlates with increased metastatic potential in thyroid cancer.
• CD82 may function as a prognostic marker for metastasis in thyroid cancer.
• CD63 does not appear to play a direct role in thyroid carcinogenesis.